Share this to:

Support & Insight for the Autumn of Life

Alzheimer’s Drugs: Risky for Other Memory Problems?

MEDICATION:

New insights in using Alzheimer’s drugs for other memory problems shows why these medications are no simple memory patch.


When people experience memory loss that looks a little like Alzheimer’s but isn’t, doctors diagnose it as “Mild Cognitive Impairment (MCI)”. Some prescribe the Alzheimer’s drug donepezil (Aricept&reg). But research shows why it should not be prescribed for people with mild cognitive impairment (MCI) without a genetic test.

UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.

When It Isn’t Alzheimer’s

Mild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer’s disease, some physicians prescribe donepezil, which is marketed under the brand name Aricept and is the most-prescribed medication for Alzheimer’s. Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study published in 2005, but it was not approved by the FDA. Still, doctors have often prescribed the drug “off-label” — meaning that it is not approved for that specific disorder — for their patients with mild cognitive impairment.

Worse Instead of Better

From data collected during the 2005 trial, the researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes, they found that people with the genetic variation who were treated with donepezil had greater changes in their scores than those who took placebos. They also found that those who took donepezil had a faster cognitive decline than those who took the placebo.

Benefits versus Risks – Ask Your Doctor

Physicians are increasingly using personalized medicine, including pharmacogenetics — the study of how genetics affect a person’s response to a drug — to tailor their patients’ care. The findings reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients.

  • SOURCE:
    UCLA School of Nursing
  • AUTHORS:

    The study was led by Sophie Sokolow, an associate professor at the UCLA School of Nursing. Co-authors were Ziaohui Li, Lucia Chen, Kent Taylor and Jerome Rotter, all of UCLA.
  • REFERENCE JOURNAL:

    The study was published in the Journal of Alzheimer’s Disease.
  • FUNDING:

    The work was supported by the National Institute on Aging (grant 1K23AG05141601A1).
Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

LITHIUM.png
Lithium May Halt Progression of Alzheimer's Disease
A study at McGill University shows that lithium given in micro doses may be capable of both halting signs of advanced...
160128-rivastigmin.jpeg
Prevent Falls in Parkinson's with Rivastigmine for Dementia
People with Parkinson's were given the oral drug rivastigmine (brand name Exelon®). They were 45% less likely to fall...
160509-meds2.jpeg
Best Time to Stop Medicine for Dementia

Books

Amazon Books
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter